(Q30364932)

English

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 June 2017

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. (English)

1 reference

Europe PubMed Central

20 June 2017

phase I clinical trial

0 references

0 references

Sebastian Maurer-Stroh

13

0 references

object named as

Eng Eong Ooi

3

0 references

Martin F. Bachmann

10

object named as

Martin Bachmann

1 reference

Europe PubMed Central

20 June 2017

Philippe Saudan

9

object named as

Philippe Saudan

1 reference

Europe PubMed Central

20 June 2017

1

object named as

Jenny G H Low

1 reference

Europe PubMed Central

20 June 2017

author name string

Lawrence S Lee

2

1 reference

Europe PubMed Central

20 June 2017

Kantharaj Ethirajulu

4

1 reference

Europe PubMed Central

20 June 2017

Pauline Yeo

5

1 reference

Europe PubMed Central

20 June 2017

Alex Matter

6

1 reference

Europe PubMed Central

20 June 2017

John E Connolly

7

1 reference

Europe PubMed Central

20 June 2017

David A G Skibinski

8

1 reference

Europe PubMed Central

20 June 2017

Brendon J Hanson

11

1 reference

Europe PubMed Central

20 June 2017

Qingshu Lu

12

1 reference

Europe PubMed Central

20 June 2017

Sam Lim

14

1 reference

Europe PubMed Central

20 June 2017

Veronica Novotny-Diermayr

15

1 reference

Europe PubMed Central

20 June 2017

language of work or name

0 references

publication date

18 July 2014

1 reference

Europe PubMed Central

20 June 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

20 June 2017

32

1 reference

Europe PubMed Central

20 June 2017

39

1 reference

Europe PubMed Central

20 June 2017

5041-5048

1 reference

Europe PubMed Central

20 June 2017

Emergence and pandemic potential of swine-origin H1N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Influenza: options to improve pandemic preparation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Influenza vaccines for the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Influenza virosomes as vaccine adjuvant and carrier system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Advances in the development of universal influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Versatile virus-like particle carrier for epitope based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A vaccine against nicotine for smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A novel fed-batch based cultivation method provides high cell-density and improves yield of soluble recombinant proteins in shaken cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Bacterially produced recombinant influenza vaccines based on virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Quantitative review of antibody response to inactivated seasonal influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A prime-boost vaccination of mice with heterologous H5N1 strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.011

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.07.011

1 reference

Europe PubMed Central

20 June 2017

1 reference

Europe PubMed Central

20 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30364932&oldid=1767815648"